Abbott Laboratories announced Monday it received approval from the U.S. Food and Drug Administration for two new continuous glucose monitoring systems, including one for people who don't have diabetes.
A continuous glucose monitor, or a CGM, is a small sensor that pokes through the skin and tracks a person's glucose levels in real time.
One of Abbott's new systems, Libre Rio, is for patients with Type 2 diabetes who do not take insulin.
Oftentimes, users need a valid CGM prescription to participate in these programs, so Abbott's new over-the-counter offering could be more accessible for some consumers.
Abbott competitor Dexcom , which also sells CGM systems, received FDA approval for its first-ever over-the-counter CGM in March.
Persons:
Robert B, Ford, Abbott, Abbot, Lingo, Dexcom
Organizations:
Abbott Laboratories, U.S . Food, Drug Administration, Libre
Locations:
Vegas, Las Vegas , Nevada, U.S, Libre Rio